Find your next paid study

Vanderbilt University Medical CenterNCT07674758

Actual pay is set by the research site.

Duchenne Outcomes Research Interchange Data Enrichment Through EHR Extraction

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) th…

Duchenne Muscular Dystrophy (DMD)Becker Muscular DystrophyDystrophinopathy+1 more

The Duchenne RegistryNCT07609394

~$10 – $1,125

Actual pay is set by the research site.

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes i…

Spinal Muscular Atrophy Type 3Duchenne Muscular Dystrophy (DMD)

Columbia UniversityNCT06839469

Actual pay is set by the research site.

Duchenne Muscular Dystrophy Quality of Life: Qualitative Interviews With Patients and Caregivers

The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective …

Red Nucleus Enterprise Solutions, LLCNCT06925269

~$10 – $1,050

Actual pay is set by the research site.

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of DYNE-251 Administered Intravenously in Ambulatory Male Participants 4 to 18 Years of Age With Duchenne Muscular Dystrophy Amenable to Exon-51 Skipping

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks…

Duchenne Muscular Dystrophy (DMD)Muscular Dystrophy, DuchenneMuscular Dystrophy (DMD)+10 more

~$50 – $2,100

Actual pay is set by the research site.

Phase 1

duCHennE caRdiomyopathy mItigation Sglt2 inHibitor

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is curren…

Vanderbilt University Medical CenterNCT07172971

~$150 – $3,000

Actual pay is set by the research site.

Observational

Non-invasive Evaluation of Urinary Titin as an IND-enabling Biomarker for Use in Duchenne Muscular Dystrophy (DMD) Clinical Trials

A universal challenge in clinical investigation of novel therapeutics is the need for quantitative, objective biomarkers that directly address the mechanisms o…

Duchenne Muscular Dystrophy (DMD)Becker's Muscular Dystrophy (BMD)

Children's Hospital of PhiladelphiaNCT07332013

Actual pay is set by the research site.

Phase 1

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death. Approximate…

Vanderbilt University Medical CenterNCT07642635

~$150 – $3,000

Actual pay is set by the research site.

The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy

The aim of the BABY DUCHENNE study is to evaluate the natural history and characterize the early clinical outcomes in very young children (0-3 years) with Duch…

University of RochesterNCT07092540

Actual pay is set by the research site.

Phase 2

An Open-Label Long-Term Follow-up Study of SAT-3247 in Patients With Duchenne Muscular Dystrophy (DMD) Including Those Who Participated in SAT-3247-CL-101

This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD including those who previously participated in S…